The worst side effects of Mounjaro: what clinical evidence and UK guidance tell us

What the trial data and MHRA guidance say about the most severe risks

The SURMOUNT-1 trial (which followed over 2,500 adults taking tirzepatide for 72 weeks) captured a detailed side-effect profile across thousands of participants. Gastrointestinal events were the most frequently reported, but the trial and subsequent post-market monitoring have also flagged rarer, more serious outcomes that anyone considering this treatment deserves to understand plainly.

In January 2026, the MHRA issued a Drug Safety Update for GLP-1 receptor agonists, including tirzepatide, specifically highlighting acute pancreatitis. It is an infrequent complication, but it can be serious. The hallmark symptom is severe, persistent stomach pain that radiates to the back, sometimes accompanied by vomiting. That pattern warrants a 999 call or an emergency department visit, not a wait-and-see approach. The NHS medicines page for tirzepatide lists pancreatitis under side effects that require immediate medical attention.

Other serious, though uncommon, events in the safety literature include gallbladder problems (gallstones and cholecystitis), acute kidney injury secondary to severe dehydration, and hypersensitivity reactions ranging from skin rash to anaphylaxis. If you develop swelling of the face, lips or throat, or difficulty breathing, stop treatment and get emergency help. These events are not common, but knowing the warning signs costs nothing and may matter enormously.

Tirzepatide carries a Black Triangle (▼) designation from the MHRA, meaning it is subject to additional monitoring while longer-term post-market data accumulates. That is standard for recently approved medicines, not a signal that the medicine is unsafe, but it does mean reporting suspected side effects via Yellow Card actively contributes to the national safety picture.

The side effects most people actually experience, and when they tend to peak

For the majority of people, the worst thing about starting Mounjaro is the first few weeks of nausea. The gut symptoms (nausea, vomiting, diarrhoea, constipation, indigestion, reflux and burping) are the most reported experiences across clinical trials and real-world use alike. They tend to be most noticeable after the very first injection and again after each dose increase as the body adjusts.

The graduated dosing schedule is designed precisely to reduce this burden. Treatment begins at 2.5mg, a tolerability dose whose job is to let your system settle rather than to produce significant weight loss. The mechanism behind these gut effects is directly related to how tirzepatide works: it slows the rate at which food leaves the stomach, which suppresses appetite but can also cause discomfort, particularly when the dose first climbs.

Other commonly reported symptoms include fatigue, headache and dizziness. Injection-site reactions (redness, itching or mild swelling at the site of the jab) are also noted in the data. Rotating between the abdomen, thigh and upper arm helps reduce localised irritation.

The good news backed by trial evidence is that for most people these symptoms are mild to moderate and transient. A useful framing from our clinical team: side effects that are manageable and improving are different from side effects that are severe, not improving or alarming. The line between those two categories is what the guidance below is about. You can read a fuller breakdown of the complete Mounjaro side-effect profile if you want the whole picture before making a decision, and our page covering the 5 Mounjaro side effects that come up most often is a good place to start if you want a quick, focused overview.

When to get medical help, and what can wait

Some symptoms need urgent attention. Seek emergency care or call 999 if you experience severe, persistent abdominal pain that reaches into your back (pancreatitis), signs of a serious allergic reaction (throat swelling, difficulty breathing, rapid heartbeat), or symptoms of significant dehydration after repeated vomiting or diarrhoea, confusion, no urination, extreme dizziness.

Contact your prescriber or GP the same day for gallbladder-type pain (sharp pain in the upper right abdomen, particularly after eating), any sudden changes in vision, low mood or thoughts of self-harm, or injection-site reactions that are spreading or worsening rather than settling. The NHS guidance on tirzepatide safety sets out these categories clearly and is worth reading before you start.

If you simply feel nauseated after your first or second pen, that is common, expected and usually manageable with small meals, slow eating and staying hydrated. It is not a reason to stop without speaking to your prescriber first, stopping abruptly after a dose increase can be addressed more safely with clinical support than alone. Our aftercare team is available seven days a week if something doesn't feel right between reviews.

For anyone curious about whether symptoms ever disappear entirely over time, the question of long-term side effects with Mounjaro is worth understanding before you commit to treatment.

How nume's clinical process addresses side-effect risk from the start

Side-effect risk is not the same for every person. Medical history (including a history of pancreatitis, certain gut conditions, gallbladder disease, or specific medications) changes the clinical picture. That is exactly why Mounjaro requires a prescription rather than being available to buy freely, and why a proper consultation matters.

At nume, every consultation is reviewed personally by a GPhC-registered Independent Prescriber before treatment is approved or dispensed. A real clinician reads your answers; there is no automated approval system. Contraindications are checked, questions about your history are taken seriously, and the prescriber decides whether treatment is appropriate for you specifically.

When a prescription is approved, your pen is dispatched the same day (for orders placed before noon, Monday to Friday) and arrives via tracked DPD delivery the next working day in plain, unbranded packaging. You will know exactly when it lands. That speed matters because timely access to a genuine, licensed supply chain (rather than an unverified source) is itself a safety consideration when it comes to medication quality.

Our prescribers discuss suitability and side effects as part of every consultation. If you want to understand how your own medical history interacts with tirzepatide's risk profile before committing to anything, start your free consultation and get a clinical answer rather than a general one. You can also learn more about overall Mounjaro safety or explore whether there are patients who experience few or no side effects.